Outlook Therapeutics (NASDAQ:OTLK) reported quarterly earnings results on February 17, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.22, missing the consensus estimate of $-0.17 by $0.05 per share. Revenue came in at -1208000.0, missing the estimate of $3.4M.
Outlook Therapeutics's stock moved following the earnings release. The stock currently trades at $0.39 with a market capitalization of $89.3M.